Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273). However, Phase 3 studies are insufficient to detect rare adverse events (AEs). A liter...
Saved in:
Main Authors: | Angel Shabu (Author), Prasad S. Nishtala (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
by: Angel Shabu, et al.
Published: (2023) -
Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination
by: Tyng-Shiuan Hsieh, et al.
Published: (2023) -
Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
by: Masahiro Iwata, et al.
Published: (2023) -
Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
by: Joyce Kong, et al.
Published: (2021) -
Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
by: Leelakrishna Channa, BS, et al.
Published: (2021)